EVNIN LUKE sold $15K of HOWL (indirect holdings)
EVNIN LUKE sold 36,387 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.42 on 2026-05-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on director selling activity; however, the presence of a pre-arranged 10b5-1 plan generally lowers the probability that the trade signals new negative information.
Market read
Traders may briefly reassess insider activity sentiment, but absent other catalysts, the event is unlikely to drive a sustained repricing.
What to watch
Assess whether there are multiple recent insider transactions, changes in volume/price around the sale date, or concurrent company-specific catalysts not mentioned here.
Background
The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics, Inc. (HOWL).
Ticker impact
Werewolf Therapeutics director EVNIN LUKE sold 36,387 HOWL shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any move would be small and driven more by broader sentiment than this single sale.
The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and the disclosed value (~$15.3K) is not large enough to imply a fundamental change by itself.
Market effects
Minimal—single-company insider sale without accompanying operational or clinical news.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than negative expectations.
Key entities
- issuerWerewolf Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure (HOWL).
- directorEVNIN LUKE
Director who executed an open-market sale of 36,387 shares under a 10b5-1 plan.
